Abstract
Rare disease drug approvals have accelerated significantly since the passage of the 1983 Orphan Drug Act (ODA). This study aims to analyze the characteristics of orphan drugs designations and approvals in the U.S. market during the period 1983–2020 and to assess the factors explaining the trends in orphan drug approvals.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
